PT-141, known by its drug name bremelanotide, holds a distinct position on this site: it’s the one compound here that’s actually FDA-approved, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, under the brand name Vyleesi. That approval status is worth understanding before anything else.
How It’s Different From Everything Else on This Site
Unlike the research-use compounds covered elsewhere on FemPeptides, bremelanotide went through the full FDA approval process and is available by prescription for HSDD specifically in premenopausal women. Research-grade PT-141 sold outside that regulated pathway is not the same quality-controlled, prescribed product.
The Mechanism
PT-141 works centrally, through melanocortin receptor activation in the brain, rather than through the vascular mechanism that drives most male sexual-function medications. That’s the mechanistic reason it’s specifically studied and approved for desire (the “hypoactive desire” part of HSDD) rather than a purely physical arousal pathway.
What to Realistically Expect
Bremelanotide is typically self-administered as needed, roughly 45 minutes before anticipated sexual activity, rather than daily. Commonly reported side effects in clinical trial data include nausea, flushing, and headache, with nausea being the most frequently reported.
The Prescribed vs Research-Use Distinction Matters Here More Than Usual
Because bremelanotide is FDA-approved, the strong recommendation for anyone interested in it is the prescribed pathway through a licensed provider rather than research-use sourcing — unlike some other compounds on this site where prescribed access simply isn’t yet available.